Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis

Acta Neurologica Scandinavica

Volumn 114, Issue 2, 2006, Pages 109-113

  Moreira, M A ^a,c   Tilbery, C P ^b   Monteiro, L P ^a   Teixeira, M M ^a   Teixeira, A L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Division of Neurology   (Brazil)

^c CIEM MS Research   (Brazil)

Author keywords

CCL2; Chemokines; Corticosteroids; CXCL10; Methylprednisolone; Multiple sclerosis

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GENERAL CONDITION IMPROVEMENT; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE;

ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; CONTROLLED CLINICAL TRIALS; DOWN-REGULATION; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 33745863552     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00629.x     Document Type: Article

References (27)

1. LASSMANN H, RANSOHO RM. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol 2004;25:132-7.
2. HAFLER DA. Multiple sclerosis. J Clin Invest 2004;113:788-94.
3. SORENSEN TL, RANSOHO RM. Etiology and pathogenesis of multiple sclerosis. Semin Neurol 1998;18:287-95.
4. PIRKO I, RODRIGUEZ M. Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial. Arch Neurol 2004;61:1148-9.
5. KOPKE S, HEESEN C, KASPER J, MUHLHAUSER I. Steroid treatment for relapses in multiple sclerosis: the evidence urges shared decision-making. Acta Neurol Scand 2004;110:1-5.
6. MILLER DM, WEINSTOCK-GUTTMAN B, BETHOUX F et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000;6:267-73.
7. LUSTER A. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
8. MACKAY CR. Chemokines: immunology's high impact factors. Nat Immunol 2001;2:95-101.
9. MOSER B, WOLF M, WALZ A, LOETSCHER P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004;25:75-84.
10. MURPHY PM, BAGGIOLINI M, CHARO IF et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-76.
11. RANSOHO RM. The chemokine system in neuroinflammation: an update. J Infect Dis 2002;186:S152-6.
12. SORENSEN TL, SELLEBJERG F, JENSEN CV et al. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 2001;8:665-72.
13. FRANCIOTTA D, MARTINO G, ZARDINI E et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001;115:192-8.
14. CALLEGARO D, GOLDBAUM M, MORAIS L et al. The prevalence of multiple sclerosis in the city of São Paulo, Brazil, 1997. Acta Neurol Scand 2001;104:208-13.
15. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
16. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
17. SIPE JC, KNOBLER RL, BRAHENY SL et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-72.
18. HAUSER SL, DAWSON DM, LEHRICH JR et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-80.
19. TEIXEIRA AL JR, CARDOSO F, SOUZA AL, TEIXEIRA MM. Increased serum concentrations of monokine induced by interferon-gamma/CXCL9 and interferon-gamma-inducible protein 10/CXCL10 in Sydenham's chorea patients. J Neuroimmunol 2004;150:157-62.
20. SELLEBJERG F, SORENSEN TL. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 2003;61:347-55.
21. MAHAD DJ, HOWELL SJL, WOODROOFE MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;72:498-502.
22. SCARPINI E, GALIMBERTI D, BARON P et al. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci 2002;195:41-6.
23. NARIKAWA K, MISU T, FUJIHARA K, NAKASHIMA I, SATO S, ITOYAMA Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004;149:182-6.
24. MAHAD DJ, LAWRY J, HOWELL SJL, WOODROOFE MN. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult Scler 2003;9:189-98.
25. TREBST C, RANSOHO RM. Investigating chemokines and chemokines receptors in patients with multiple sclerosis. Arch Neurol 2001;58:1975-80.
26. FELIPE E, MENDES MF, MOREIRA MA, TILBERY CP. Análise comparativa entre duas escalas de avaliação clínica na esclerose múltipla. Revisão de 302 casos. Arq Neuropsiquiatr 2000;58:300-3.
27. BARTOSIK-PSUJEK H, STELMASIAK Z. Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapses. Eur Neurol 2004;52:237-41.